Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102


Prognostic Values of Inflammatory and Redox Status Biomarkers on the Risk of Major Lower-Extremity Artery Disease in Individuals With Type 2 Diabetes.

Nativel M, Schneider F, Saulnier PJ, Gand E, Ragot S, Meilhac O, Rondeau P, Burillo E, Cournot M, Potier L, Velho G, Marre M, Roussel R, Rigalleau V, Mohammedi K, Hadjadj S.

Diabetes Care. 2018 Oct;41(10):2162-2169. doi: 10.2337/dc18-0695. Epub 2018 Aug 2.


Association of serum concentration of TNFR1 with all-cause mortality in patients with type 2 diabetes and chronic kidney disease: follow-up of the SURDIAGENE Cohort.

Saulnier PJ, Gand E, Ragot S, Ducrocq G, Halimi JM, Hulin-Delmotte C, Llaty P, Montaigne D, Rigalleau V, Roussel R, Velho G, Sosner P, Zaoui P, Hadjadj S; SURDIAGENE Study Group.

Diabetes Care. 2014 May;37(5):1425-31. doi: 10.2337/dc13-2580. Epub 2014 Mar 12.


Markers of fibrinolysis may predict development of lower extremity arterial disease in patients with diabetes: A longitudinal prospective cohort study with 10 years of follow-up.

Rautio A, Boman K, Eriksson JW, Svensson MK.

Diab Vasc Dis Res. 2016 May;13(3):183-91. doi: 10.1177/1479164115618516. Epub 2016 Jan 27.


Angiopoietin-related growth factor is independently associated with lower extremity peripheral arterial disease.

Nie H, Liang Y, Wang HX, Ren HL, Wang YW, Li FD, Zheng YH.

J Diabetes Complications. 2017 Feb;31(2):433-438. doi: 10.1016/j.jdiacomp.2016.10.019. Epub 2016 Oct 27.


Association of Circulating Biomarkers (Adrenomedullin, TNFR1, and NT-proBNP) With Renal Function Decline in Patients With Type 2 Diabetes: A French Prospective Cohort.

Saulnier PJ, Gand E, Velho G, Mohammedi K, Zaoui P, Fraty M, Halimi JM, Roussel R, Ragot S, Hadjadj S; SURDIAGENE Study Group.

Diabetes Care. 2017 Mar;40(3):367-374. doi: 10.2337/dc16-1571. Epub 2016 Dec 20.


Circulating Concentrations of Redox Biomarkers Do Not Improve the Prediction of Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus.

Cournot M, Burillo E, Saulnier PJ, Planesse C, Gand E, Rehman M, Ragot S, Rondeau P, Catan A, Gonthier MP, Feigerlova E, Meilhac O, Hadjadj S.

J Am Heart Assoc. 2018 Feb 25;7(5). pii: e007397. doi: 10.1161/JAHA.117.007397.


Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study.

Mohammedi K, Woodward M, Hirakawa Y, Zoungas S, Colagiuri S, Hamet P, Harrap S, Poulter N, Matthews DR, Marre M, Chalmers J; ADVANCE Collaborative Group.

Cardiovasc Diabetol. 2016 Sep 2;15(1):129. doi: 10.1186/s12933-016-0446-x.


The receptor for advanced glycation end products and risk of peripheral arterial disease, amputation or death in type 2 diabetes: a population-based cohort study.

Malmstedt J, Kärvestedt L, Swedenborg J, Brismar K.

Cardiovasc Diabetol. 2015 Jul 28;14:93. doi: 10.1186/s12933-015-0257-5.


An integrated biochemical prediction model of all-cause mortality in patients undergoing lower extremity bypass surgery for advanced peripheral artery disease.

Owens CD, Kim JM, Hevelone ND, Gasper WJ, Belkin M, Creager MA, Conte MS.

J Vasc Surg. 2012 Sep;56(3):686-95. doi: 10.1016/j.jvs.2012.02.034. Epub 2012 May 2.


Influence of micro- and macro-vascular disease and Tumor Necrosis Factor Receptor 1 on the level of lower-extremity amputation in patients with type 2 diabetes.

Schneider F, Saulnier PJ, Gand E, Desvergnes M, Lefort N, Thorin E, Thorin-Trescases N, Mohammedi K, Ragot S, Ricco JB, Hadjadj S.

Cardiovasc Diabetol. 2018 Jun 8;17(1):81. doi: 10.1186/s12933-018-0725-9.


Elevated serum fibroblast growth factor 23 levels as an indicator of lower extremity atherosclerotic disease in Chinese patients with type 2 diabetes mellitus.

He X, Hu X, Ma X, Su H, Ying L, Peng J, Pan X, Bao Y, Zhou J, Jia W.

Cardiovasc Diabetol. 2017 Jun 15;16(1):77. doi: 10.1186/s12933-017-0559-x.


Hemoglobin A1c Testing and Amputation Rates in Black, Hispanic, and White Medicare Patients.

Suckow BD, Newhall KA, Bekelis K, Faerber AE, Gottlieb DJ, Skinner JS, Stone DH, Goodney PP.

Ann Vasc Surg. 2016 Oct;36:208-217. doi: 10.1016/j.avsg.2016.03.035. Epub 2016 Jul 27.


High hemoglobin A1c associated with increased adverse limb events in peripheral arterial disease patients undergoing revascularization.

Arya S, Binney ZO, Khakharia A, Long CA, Brewster LP, Wilson PW, Jordan WD Jr, Duwayri Y.

J Vasc Surg. 2018 Jan;67(1):217-228.e1. doi: 10.1016/j.jvs.2017.06.101. Epub 2017 Aug 31.


Association of plasma osteoprotegerin levels with the severity of lower extremity arterial disease in patients with type 2 diabetes.

Niu Y, Zhang W, Yang Z, Li X, Wen J, Wang S, Zhang H, Wang X, Zhou H, Fang W, Qin L, Su Q.

BMC Cardiovasc Disord. 2015 Aug 11;15:86. doi: 10.1186/s12872-015-0079-0.


Association of soluble tumor necrosis factor receptors 1 and 2 with nephropathy, cardiovascular events, and total mortality in type 2 diabetes.

Carlsson AC, Östgren CJ, Nystrom FH, Länne T, Jennersjö P, Larsson A, Ärnlöv J.

Cardiovasc Diabetol. 2016 Feb 29;15:40. doi: 10.1186/s12933-016-0359-8.


Association of plasma fetuin-a levels with peripheral arterial disease and lower extremity arterial calcification in subjects with type 2 diabetes mellitus.

Eleftheriadou I, Grigoropoulou P, Kokkinos A, Mourouzis I, Perrea D, Katsilambros N, Sfikakis PP, Tentolouris N.

J Diabetes Complications. 2017 Mar;31(3):599-604. doi: 10.1016/j.jdiacomp.2016.11.006. Epub 2016 Nov 12.


Skin autofluorescence as a measure of advanced glycation end products deposition predicts 5-year amputation in patients with peripheral artery disease.

de Vos LC, Boersema J, Mulder DJ, Smit AJ, Zeebregts CJ, Lefrandt JD.

Arterioscler Thromb Vasc Biol. 2015 Jun;35(6):1532-7. doi: 10.1161/ATVBAHA.115.305407. Epub 2015 Apr 16.


Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies.

Hadjadj S, Fumeron F, Roussel R, Saulnier PJ, Gallois Y, Ankotche A, Travert F, Abi Khalil C, Miot A, Alhenc-Gelas F, Lievre M, Marre M; DIABHYCAR Study Group; DIAB2NEPHROGENE Study Group; SURDIAGENE Study Group.

Diabetes Care. 2008 Sep;31(9):1847-52. doi: 10.2337/dc07-2079. Epub 2008 Jun 3.


C-reactive protein and brain natriuretic peptide as predictors of adverse events after lower extremity endovascular revascularization.

Stone PA, Schlarb H, Campbell JE, Williams D, Thompson SN, John M, Campbell JR, AbuRahma AF.

J Vasc Surg. 2014 Sep;60(3):652-60. doi: 10.1016/j.jvs.2014.03.254. Epub 2014 Apr 29.

Supplemental Content

Support Center